Xun Chen, Weidong Du, Jie Wu, Lejia Zhang, Yunyang Lu, Xiliu Zhang, Chao Wang, Shangwu Chen, Dongsheng Yu, Wei Zhao
{"title":"Deletion of GPX8 Enhances Irradiation-Induced Ferroptosis Through m<sup>6</sup>A Hypomethylation-Mediated Upregulation of ACSL4 in Oral Cancer.","authors":"Xun Chen, Weidong Du, Jie Wu, Lejia Zhang, Yunyang Lu, Xiliu Zhang, Chao Wang, Shangwu Chen, Dongsheng Yu, Wei Zhao","doi":"10.1177/15230864261449406","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Radioresistance limits the therapeutic efficacy of radiotherapy, and although ferroptosis contributes to radiation-induced tumor suppression, the upstream redox-epitranscriptomic mechanisms remain poorly defined. This study investigated how loss of the antioxidant enzyme glutathione peroxidase 8 (GPX8) influences susceptibility to ionizing radiation (IR), delineated the molecular pathway linking oxidative stress to ferroptosis, and evaluated the potential of GPX8 deletion as a radiosensitization strategy.</p><p><strong>Results: </strong>We identify GPX8 as a previously unrecognized suppressor of ferroptosis whose deletion markedly amplifies IR-induced ferroptotic cell death. GPX8 deficiency increased reactive oxygen species accumulation, lipid peroxidation, labile iron levels, and ferroptosis-associated gene expression following irradiation. Mechanistic dissection revealed a novel redox-epitranscriptomic axis: oxidative stress induced by GPX8 loss downregulated the transcription factor E2F4, which in turn reduced zinc-finger CCCH-type containing 13 (ZC3H13) expression, leading to N<sup>6</sup>-methyladenine (m<sup>6</sup>A) hypomethylation and stabilization of acyl-CoA synthetase long-chain family member 4 (ACSL4) mRNA. Overexpression of E2F4 or ZC3H13 reversed ACSL4 upregulation, confirming pathway causality. ACSL4 knockdown diminished ferroptosis and rescued the hypersensitivity of GPX8-deficient cells to IR. In an orthotopic xenograft model, GPX8-knockout tumors displayed significantly enhanced radiosensitivity and elevated ferroptotic markers, effects mitigated by the ferroptosis inhibitor liproxstatin-1.</p><p><strong>Innovation: </strong>This work uncovers a previously uncharacterized antioxidant-m<sup>6</sup>A-ferroptosis regulatory pathway and provides the first evidence that GPX8 modulates radiotherapy response by epitranscriptomic control of ACSL4 stability <i>via</i> the E2F4-ZC3H13 axis.</p><p><strong>Conclusion: </strong>GPX8 deletion sensitizes oral cancer to irradiation by promoting ferroptosis through oxidative stress-driven suppression of E2F4 and ZC3H13, resulting in m<sup>6</sup>A hypomethylation and stabilization of ACSL4 mRNA. GPX8 thus represents a promising target for ferroptosis-based radiosensitization. <i>Antioxid. Redox Signal.</i> 45, 219-241.</p>","PeriodicalId":8011,"journal":{"name":"Antioxidants & redox signaling","volume":" ","pages":"219-241"},"PeriodicalIF":6.8000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antioxidants & redox signaling","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1177/15230864261449406","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: Radioresistance limits the therapeutic efficacy of radiotherapy, and although ferroptosis contributes to radiation-induced tumor suppression, the upstream redox-epitranscriptomic mechanisms remain poorly defined. This study investigated how loss of the antioxidant enzyme glutathione peroxidase 8 (GPX8) influences susceptibility to ionizing radiation (IR), delineated the molecular pathway linking oxidative stress to ferroptosis, and evaluated the potential of GPX8 deletion as a radiosensitization strategy.
Results: We identify GPX8 as a previously unrecognized suppressor of ferroptosis whose deletion markedly amplifies IR-induced ferroptotic cell death. GPX8 deficiency increased reactive oxygen species accumulation, lipid peroxidation, labile iron levels, and ferroptosis-associated gene expression following irradiation. Mechanistic dissection revealed a novel redox-epitranscriptomic axis: oxidative stress induced by GPX8 loss downregulated the transcription factor E2F4, which in turn reduced zinc-finger CCCH-type containing 13 (ZC3H13) expression, leading to N6-methyladenine (m6A) hypomethylation and stabilization of acyl-CoA synthetase long-chain family member 4 (ACSL4) mRNA. Overexpression of E2F4 or ZC3H13 reversed ACSL4 upregulation, confirming pathway causality. ACSL4 knockdown diminished ferroptosis and rescued the hypersensitivity of GPX8-deficient cells to IR. In an orthotopic xenograft model, GPX8-knockout tumors displayed significantly enhanced radiosensitivity and elevated ferroptotic markers, effects mitigated by the ferroptosis inhibitor liproxstatin-1.
Innovation: This work uncovers a previously uncharacterized antioxidant-m6A-ferroptosis regulatory pathway and provides the first evidence that GPX8 modulates radiotherapy response by epitranscriptomic control of ACSL4 stability via the E2F4-ZC3H13 axis.
Conclusion: GPX8 deletion sensitizes oral cancer to irradiation by promoting ferroptosis through oxidative stress-driven suppression of E2F4 and ZC3H13, resulting in m6A hypomethylation and stabilization of ACSL4 mRNA. GPX8 thus represents a promising target for ferroptosis-based radiosensitization. Antioxid. Redox Signal. 45, 219-241.
期刊介绍:
Antioxidants & Redox Signaling (ARS) is the leading peer-reviewed journal dedicated to understanding the vital impact of oxygen and oxidation-reduction (redox) processes on human health and disease. The Journal explores key issues in genetic, pharmaceutical, and nutritional redox-based therapeutics. Cutting-edge research focuses on structural biology, stem cells, regenerative medicine, epigenetics, imaging, clinical outcomes, and preventive and therapeutic nutrition, among other areas.
ARS has expanded to create two unique foci within one journal: ARS Discoveries and ARS Therapeutics. ARS Discoveries (24 issues) publishes the highest-caliber breakthroughs in basic and applied research. ARS Therapeutics (12 issues) is the first publication of its kind that will help enhance the entire field of redox biology by showcasing the potential of redox sciences to change health outcomes.
ARS coverage includes:
-ROS/RNS as messengers
-Gaseous signal transducers
-Hypoxia and tissue oxygenation
-microRNA
-Prokaryotic systems
-Lessons from plant biology